Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: Clinical and preclinical studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 1, 2005, Pages 309-315

  Melichar, Jan K ^a   Hume, Susan P ^b   Williams, Tim M ^a   Daglish, Mark R C ^a   Taylor, Lindsay G ^a   Ahmad, Rabia ^b   Malizia, Andrea L ^a   Brooks, David J ^b   Myles, Judith S ^c   Lingford Hughes, Anne ^a   Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c BLACKBERRY HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPRENORPHINE; METHADONE; OPIATE AGONIST; OPIATE RECEPTOR; RADIOLIGAND; CARBON;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; ADDICTION; ANIMAL; CHEMISTRY; METABOLISM; MIDDLE AGED; OPIATE ADDICTION; SPRAGUE DAWLEY RAT; TIME;

ADULT; ANIMALS; BEHAVIOR, ADDICTIVE; CARBON RADIOISOTOPES; DIPRENORPHINE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; TIME FACTORS;

EID: 19944429408     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.072686     Document Type: Article

References (38)

1. Borgland SL, Connor M, Osborne PB, Furness JB, and Christie MJ (2003) Opioid agonists have different efficacy profiles for g protein activation, rapid desensitization and endocytosis of mu-opioid receptors. J Biol Chem 278:18776-18784.
2. Cross AJ, Hille C, and Slater P (1987) Subtraction autoradiography of opioid receptor subtypes in human brain. Brain Res 418:343-343.
3. Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, and Jones AK (1991) Compartmental analysis of diprenorphine binding to opioid receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab 11:1-9.
4. Daglish MRC, Lingford-Hughes A, Melichar J, Brooks DJ, Myles JS, and Nutt DJ (2000) Changes in opioid receptor binding during opioid detoxification. J Psychopharmacol 14:A17.
5. Delay-Goyet P, Zajac JM, Javoy-Agid F, Agid Y, and Roques BP (1987) Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and Parkinsonian subjects. Brain Res 414:8-14.
6. Eap CB, Buclin T, and Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193.
7. Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, and Baumann P (1996) Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 50:385-389.
8. Gabilondo AM, Meana JJ, Barturen F, Sastre M, and Garcia-Sevilla JA (1994) mu-Opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology 115:135-140.
9. Garrido MJ, Valle M, Calvo R, and Troconiz IF (1999) Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 288:179-187.
10. Gerrits MA, Wiegant VM, and Van Ree JM (1999) Endogenous opioids implicated in the dynamics of experimental drug addiction: an in vivo autoradiographic analysis. Neuroscience 89:1219-1227.
11. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, and Zubieta JK (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-2009.
12. Gunn RN, Lammertsma AA, Hume SP, and Cunningham VJ (1997) Parametric imaging of ligand-receptor binding using a simplified reference region model. Neuroimage 6:279-287.
13. 11C]]citalopram as a radioligand for in vivo labelling of 5-hydroxytryptamine uptake sites. Int J Rad Appl Instrum B 19:851-855.
14. 11C]-diprenorphine in normal volunteers. J Neurosci Methods 23:121-129.
15. Jones AK, Qi LY, Fujirawa T, Luthra SK, Ashburner J, Bloomfield P, Cunningham VJ, Itoh M, Fukuda H, and Jones T (1991) In vivo distribution of opioid receptors in man in relation to the cortical projections of the medial and lateral pain systems measured with positron emission tomography. Neurosci Lett 126:25-28.
16. 11C] diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. J Neurosci Methods 51:123-124.
17. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, et al. (2000) Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295:1070-1076.
18. Koepp MJ, Richardson MP, Brooks DJ, and Duncan JS (1998) Focal cortical release of endogenous opioids during reading-induced seizures. Lancet 352:952-955.
19. Lewis JW and Husbands SM (2004) The orvinols and related opioids - high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10:717-732.
20. Li JG, Raffa RB, Cheung P, Tzeng TB, and Liu-Chen LY (1998) Apparent thermodynamic parameters of ligand binding to the cloned rat mu-opioid receptor. Eur J Pharmacol 354:227-237.
21. Luthra SK, Pike VW, and Brady F (1985) The preparation of carbon-11 labelled Diprenorphine: a new radioligand for the study of the opioid receptor system in vivo. J Chem Soc Chem Commun 1423-1425.
22. Mark TL, Woody GE, Juday T, and Kleber HD (2001) The economic costs of heroin addiction in the United States. Drug Alcohol Depend 61:195-206.
23. Marsch LA (1998) The efficacy of methadone maintenance interventions in reducing illicit opioid use, HIV risk behavior and criminality: a meta-analysis. Addiction 93:515-532.
24. Maxwell S and Shinderman MS (2002) Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis 21:1-12.
25. Melichar JK, Myles JS, Eap CB, and Nutt DJ (2003a) Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol 8:59-66.
26. Melichar JK, Nutt DJ, and Malizia AL (2003b) Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol 459:217-219.
27. Nutt DJ (1997) The Neurochemistry of Addiction. Hum Psychopharmacol 12:S53-S58.
28. Pert CB, Kuhar MJ, and Snyder SH (1975) Autoradiograhic localization of the opioid receptor in rat brain. Life Sci 16:1849-1853.
29. Pfeiffer A, Pasi A, Mehraein P, and Herz A (1982) Opiate receptor binding sites in human brain. Brain Res 248:87-96.
30. Rajeawaran S, Hume SP, Cremer JE, Young J, Bailey DL, Ashburner J, Luthra SK, Jones AKP, and Jones T (1991) Dynamic monitoring of [C-11] Diprenorphine in rat-brain using a prototype positron imaging device. J Neurosci Methods 40:223-232.
31. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, and Reisine T (1994) Pharmacological characterization of the cloned kappa, delta and mu opioid receptors. Mol Pharmacol 45:330-334.
32. Robb R and Hanson D (1991) A Software System for Interactive and Quantitative Visualisation of Multidimensional Biomedical Images. Australas Phys Eng Sci Med 14:9-30.
33. Rubenstein RB, Kreek MJ, Mbawa N, Wolff WI, Korn R, and Gutjahr CL (1978) Human spinal fluid methadone levels. Drug Alcohol Depend 3:103-106.
34. 11C]-diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 11:204-219.
35. Shapira M, Keren O, Gafni M, and Sarne Y (2001) Divers pathways mediate delta-opioid receptor down regulation within the same cell. Mol Brain Res 96:142-150.
36. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, and DeVane CL (2004) Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173:132-138.
37. Zadina JE, Kastin AJ, Harrison LM, Ge LJ, and Chang SL (1995) Opiate receptor changes after chronic exposure to agonists and antagonists. Ann NY Acad Sci 757:353-361.
38. Zhou Y, Spangler R, Maggos CE, LaForge KS, Ho A, and Kreek MJ (1996) Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur Pharmacol 315:31-35.